中华临床免疫和变态反应杂志2016，Vol.10Issue(4)：371-376,6.DOI:10.3969/j.issn.1673-8705.2016.04.010
托珠单抗治疗系统性硬化症10例
Tocilizumab in Ten Patients with Systemic Sclerosis
高飞 1吴燕芳 1林禾1
作者信息
- 1. 福建省立医院风湿免疫科，福州350001
- 折叠
摘要
Abstract
Objective To observe the clinical efficacy and side effects of tocilizumab in the treatment of system-ic scelerosis.Methods Ten diffuse SSc patients (9 females and 1 male) were recruited into this obser-vational study, and tocilizumab was administered at 8 mg/kg once a month for 3 months or 6 months, the clinical and laboratorial parameters were reassessed at baseline , three month after the treatment and the last infusion .Results Five patients ( disease duration >36 months ) administered tocilizumab for 6 months, Tocilizumab induced a significant improvement in modified Rodnan skin score (mRSS) (44 vs. 27, P=0.016), digital ulcers (10 vs.2, P=0.031) and the Patient Global Assessment (PGA) (90 vs.50, P=0.0097) in these 5 patients (P<0.05).After 12 weeks'treatment for patients whose disease duration ≤12 months, the PAG improved significantly ( P<0.05 ) .The mRSS and digital ulcers also re-duced after treatment , but the difference was not statistical significant .No significant adverse drug reac-tions were seen in this observational study .Conclusion Tocilizumab appears to be effective on skin fi-brosis and digital ulcers in patients with diffuse SSc .All treatments are well tolerated .The result of this study suggests that Tocilizumab may be an alternative choice for the treatment of refractory SSc .关键词
系统性硬化症/托珠单抗Key words
systemic scleroderma/tocilizumab分类
医药卫生引用本文复制引用
高飞,吴燕芳,林禾..托珠单抗治疗系统性硬化症10例[J].中华临床免疫和变态反应杂志,2016,10(4):371-376,6.
